Vanda Pharmaceuticals Inc.

Form 4 July 19, 2007

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

January 31, Expires: 2005

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Estimated average burden hours per response... 0.5

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

Common

Stock (1)

07/17/2007

(Print or Type Responses)

CHALL CDOCC CTEVENIA		2. Issuer Name and Symbol	2. Issuer Name and Ticker or Trading			5. Relationship of Reporting Person(s) to Issuer			
(Last) (Firs	t) (Middle)	Vanda Pharmaceuticals Inc. [VNDA] 3. Date of Earliest Transaction			(Check all applicable)				
9605 MEDICAL CE SUITE 300	(Month/Day/Year) 07/17/2007	onth/Day/Year)				Owner r (specify			
(Stree	et)	4. If Amendment, Day/Year	_		6. Individual or Jos Applicable Line) _X_ Form filed by O	•			
ROCKVILLE, MD	20850				Form filed by M Person	ore than One Rep	porting		
(City) (State	e) (Zip)	Table I - Non-I	Derivative Secur	ities Acqu	iired, Disposed of	, or Beneficiall	y Owned		
	action Date 2A. Deer Day/Year) Executio any (Month/I	n Date, if Transaction Code Day/Year) (Instr. 8) Code V	4. Securities Ador(A) or Disposed (Instr. 3, 4 and (A) or Amount (D)	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Stock $\frac{(1)}{2}$ 07/17/2	2007	M	3,300 A	0.8274	3,300	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

S

3,300 D

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

D

\$ 20.63 0

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 0.8274	07/17/2007(1)		M	3,300	(2)	11/14/2015	Common Stock	3,300

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SHALLCROSS STEVEN A 9605 MEDICAL CENTER DRIVE, SUITE 300 ROCKVILLE, MD 20850

Sr. VP, CFO, Treasurer

Signatures

/s/ Steven A. O7/19/2007 Shallcross

**Signature of Reporting Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction was administered pursuant to an authorized 10b5-1 plan.
- (2) Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to an additional 2.08333% of the aggregate shares each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2